Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma

Chordoma

Image Assisted Optimization of Proton Radiation Therapy in Chordomas and Chondrosarcomas Nivolumab and Relatlimab in Treating Participants With Advanced Chordoma Anlotinib Hydrochloride Versus Imatinib Mesylate in Locally Advanced, Unresectable or Metastatic Chordoma Charged Particle RT for Chordomas and Chondrosarcomas of the Base of Skull or Cervical Spine Proton Therapy for Chordomas and/or Chondrosarcomas Afatinib in Locally Advanced and Metastatic Chordoma Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma Sacral Chordoma: Surgery Versus Definitive Radiation Therapy in Primary Localized Disease Trial of Proton Versus Carbon Ion Radiation Therapy in Patients With Chordoma of the Skull Base Hypoxia-positron Emission Tomography (PET) and Intensity Modulated Proton Therapy (IMPT) Dose Painting in Patients With Chordomas BN Brachyury and Radiation in Chordoma Pemetrexed for the Treatment of Chordoma Proton Radiation for Chordomas and Chondrosarcomas QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma. Proton Beam Therapy for Chordoma Patients Efficacy and Safety of Imatinib in Chordoma QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine Chordoma Nilotinib With Radiation for High Risk Chordoma Chordoma Family Study Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma CDK4/6 Inhibition in Locally Advanced/Metastatic Chordoma Genetic Aspects of Chordoma: A Collaboration With SEER Registries to Identify Chordoma Families